<DOC>
	<DOC>NCT00273039</DOC>
	<brief_summary>The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder</brief_summary>
	<brief_title>A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<criteria>Patients with Generalized Social Anxiety Disorder as the primary diagnosis. If female, must commit to consistent and correct use of an acceptable method of birth control. Patients with any other psychiatric disorder as a primary diagnosis or within 6 months prior to screening. Patients with Body Dysmophic Disorder, Schizophrenia, Schizoaffective Disorder, or a Bipolar Disorder. Patients who pose a current suicidal or homicidal risk or have made a suicide attempt within the past 6 months or have ever been homicidal. Patients who have a positive urine test at screen for illegal drug use and/or a history of substance abuse or dependence (alcohol or drugs) within the past 12 months. Patients with an unstable medical disorder. Female patients who are pregnant, lactating, or planning to become pregnant during a specified time during the study. Patients who are taking other psychoactive medications.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Psychiatry</keyword>
</DOC>